Last updated: 11/07/2018 16:57:18
A Randomized, Double-Blind, Parallel-Group, Comparative Trial Evaluating Fluticasone Propionate (220mcgBID), Triamcinolone Acetonide (600mcg BID), and Fluticasone Propionate (88mcg BID) in Combination withSalmeterol Xinafoate (42mcg BID), Each Delivered Via A Metered-Dose Inhaler
Clinicaltrials.gov ID
Not applicable
EudraCT ID
Not applicable
EU CT Number
Not applicable
Trial status
Study complete
Study complete
Trial overview
Official title: A Randomized, Double-Blind, Parallel-Group, Comparative Trial Evaluating Fluticasone Propionate (220mcgBID), Triamcinolone Acetonide (600mcg BID), and Fluticasone Propionate (88mcg BID) in Combination withSalmeterol Xinafoate (42mcg BID), Each Delivered Via A Metered-Dose Inhaler
Trial description: A Randomized, Double-Blind, Parallel-Group, Comparative Trial Evaluating Fluticasone Propionate (220mcgBID), Triamcinolone Acetonide (600mcg BID), and Fluticasone Propionate (88mcg BID) in Combination withSalmeterol Xinafoate (42mcg BID), Each Delivered Via A Metered-Dose Inhaler
Primary purpose:
Not applicable
Trial design:
Not applicable
Masking:
Not applicable
Allocation:
Not applicable
Primary outcomes:
Not applicable
Secondary outcomes:
Not applicable
Interventions:
Not applicable
Enrollment:
Not applicable
Primary completion date:
Not applicable
Observational study model:
Not applicable
Time perspective:
Not applicable
Clinical publications:
Baraniuk J; Murray JJ; Nathan RA; Berger WE; Johnson M; Edwards LD; Srebro S; Rickard KA. Fluticasone alone or in combination with salmeterol vs triamcinolone in asthma. Chest 1999;116(3):625-632.
Cook D; Srebro SH; Rogenes PR; Rickard K; Edwards L; Johnson MC. Am. J. Respir. Crit. Care Med 1998;157(3):A416.
Friedman B; Rogenes PR; Srebro S; Edwards L; Johnson MC. Patients with mild to moderate persistent asthma who were symptomatic despite taking inhaled corticosteroids achieved a greater improvement in pulmonary function with fluticasone propionate than wi
Inclusion and exclusion criteria
Trial location(s)
This study does not involve prospective enrollment of participants.
Study documents
Scientific result summary
Available language(s): English
If you wish to request for full study report, please contact - [email protected]
Results overview
Not applicable
Recruitment status
Study complete
Actual primary completion date
Not applicable
Actual study completion date
1997-28-07
Plain language summaries
Plain language summaries of clinical trial results for Phase 2-4 clinical trials that were initiated on or after January 2022 will be posted by GSK within one year following study completion.
Additional information about the trial
Not applicable
Participate in clinical trial
Access to clinical trial data by researchers
Visit website